AU Patent

AU2022284369A1 — Inhibitors of bruton's tyrosine kinase and methods of their use

Assigned to Janssen Pharmaceutica NV · Expires 2024-01-25 · 2y expired

What this patent protects

The present disclosure is directed to the use of a compound of Formula (III) in the treatment of malignancies.

USPTO Abstract

The present disclosure is directed to the use of a compound of Formula (III) in the treatment of malignancies.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022284369A1
Jurisdiction
AU
Classification
—
Expires
2024-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.